Prostate Cancer Trial, Recruiting NCT06828263 Sponsor: University Hospital, Grenoble Condition: Prostate Cancer
Back to Prostate Cancer

Prostate Cancer Trial, Recruiting

NCT06828263
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adults aged 18 or older who have been diagnosed with prostate cancer of a specific type called adenocarcinoma
  • People whose prostate cancer has spread to other parts of the body, is no longer responding to treatments that lower testosterone (castration-resistant), and is getting worse over time
  • People whose cancer did not respond well to, or who could not tolerate, certain hormone-blocking drugs (such as abiraterone, enzalutamide, apalutamide, or darolutamide)
  • People who have previously received at least one course of a specific type of chemotherapy (taxane-based), OR people who are experiencing symptoms but whose doctor has assessed them as not well enough to have chemotherapy
  • People whose general health and ability to carry out daily activities falls within a certain range, rated 0 to 2 on a standard medical scale (meaning anywhere from fully active to capable of some self-care but limited in physical activity) (confirm with trial site)

Who may not be able to join:

  • People who do not agree to have their personal data used for clinical research purposes

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 04 76 76 54 55

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
1 August 2023
Est. completion
1 June 2043

Where this trial is recruiting

🇫🇷 France

Primary endpoints

Confirm prospectively the prognostic value of post-therapy SPECT/CT imaging for response evaluation during [177Lu]Lu- PSMA

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov